| TITLE |
DATE |
| Incyte to Present at the Oppenheimer & Co. 22nd
AnnualHealthcare Conference |
30-Nov-2011 |
| Incyte to Present at the 23rd Annual Piper Jaffray Health Care Conference |
18-Nov-2011 |
| FDA Approves Incyte's Jakafi(TM) (ruxolitinib) for Patients with Myelofibrosis |
16-Nov-2011 |
| Incyte Reports Third Quarter 2011 Financial Results and Provides Update
on Key Clinical Programs |
27-Oct-2011 |
| Incyte to Report Third Quarter 2011 Financial Results and Provide Update on Key Clinical Programs on October 27 |
13-Oct-2011 |
| Incyte to Present at Upcoming Investor Conferences |
30-Aug-2011 |
| FDA Accepts NDA Filing for Ruxolitinib as a Treatment for
Myelofibrosis |
3-Aug-2011 |
| Incyte Reports Second Quarter 2011 Financial Results and Provides Update
on Key Clinical Programs |
28-Jul-2011 |
| Incyte Reports Second Quarter 2011 Financial Results andProvides
Update on Key Clinical Programs on July 28 |
13-Jul-2011 |
| Incyte Reports Additional Analyses of Symptomatic Improvement andQuality
of Life with Ruxolitinib (INC424) in Patients with Myelofibrosis from
the COMFORT-I Study |
11-Jun-2011 |
| Incyte Submits New Drug Application for Ruxolitinib in Myelofibrosis to the US Food and Drug Administration |
6-Jun-2011 |
| Incyte Announces Ruxolitinib (INC424) Shows Significant Clinical
Benefit for Myelofibrosis Patients in Two Phase III Studies at ASCO
Annual Meeting |
4-Jun-2011 |
| Incyte to Present at Upcoming Investor Conferences |
24-May-2011 |
| Incyte Reports First Quarter 2011 Financial Results and Program
Updates |
3-May-2011 |
| Incyte to Present at the Bank of America Merrill Lynch Healthcare
Conference |
27-Apr-2011 |
| Incyte to Report First Quarter 2011 Financial Results and Provide
Update on Drug Discovery & Development Programs on May 3 |
14-Apr-2011 |
| Incyte Achieves $15 Million Milestone for c-MET Inhibitor Oncology
Program |
5-Apr-2011 |
| Incyte's Ruxolitinib (INCB18424) Meets Primary Endpoint in Second
Phase III Study |
15-Mar-2011 |
| Incyte to Present at the Cowen and Company 31st
Annual Health Care Conference |
23-Feb-2011 |
| Incyte Reports 2010 Financial Results; Provides 2011 Key Objectives
and Financial Guidance |
10-Feb-2011 |
| Incyte to Report 2010 Financial Results and Provide 2011 Key Objectives and Financial Guidance on February 10 |
28-Jan-2011 |
| Incyte to Present at the 29th Annual J.P. Morgan Healthcare Conference |
3-Jan-2011 |
| Incyte Announces Positive Top-Line Results from COMFORT-I Pivotal
Phase III Trial of INCB18424 in Myelofibrosis, a Debilitating,
Life-Threatening Blood Cancer |
20-Dec-2010 |
| Incyte Presents Positive Long-Term Results from Ongoing Phase II
Trial of INCB18424 in Advanced Polycythemia Vera (PV) and Essential
Thrombocythemia (ET) at the American Society of Hematology Annual Meeting |
6-Dec-2010 |
| Incyte to Present at the 22nd Annual Piper Jaffray Health Care Conference |
18-Nov-2010 |
| Incyte's Selective Oral JAK1 and JAK2 Inhibitor Demonstrates Positive Phase IIa Results in Patients with Active Rheumatoid Arthritis |
10-Nov-2010 |
| Incyte to Host Webcast at 2010 ACR/ARHP Annual Scientific Meeting |
10-Nov-2010 |
| Incyte Reports Third Quarter 2010 Financial Results and Provides
Update on Drug Discovery and Development Programs |
9-Nov-2010 |
| Incyte Achieves $50 Million in Milestones for Initiation of a Joint
Global Phase III Clinical Trial of Novel JAK1 and JAK2 Inhibitor
INCB18424 in Patients with Polycythemia Vera |
2-Nov-2010 |
| Incyte to Report Third Quarter 2010 Financial Results and Provide
Update on Drug Discovery & Development Programs on November 9 |
26-Oct-2010 |
| Incyte to Present at the Oppenheimer 21st
Annual Healthcare Conference |
21-Oct-2010 |
| Incyte Achieves $19 Million Milestone as Novel JAK1 and JAK2
Inhibitor Advances into Phase IIb Development for Rheumatoid Arthritis |
20-Oct-2010 |
| Phase I/II Data Published in New England Journal of Medicine
Demonstrate that Incyte JAK Inhibitor, INCB18424, Provides Marked and
Durable Clinical Benefits in Patients with Myelofibrosis, a Rare,
Life-Threatening Blood Cancer |
15-Sep-2010 |
| Incyte Reaches Agreement with the FDA on a Special Protocol Assessment for the Phase III Clinical Trial of INCB18424 in Polycythemia Vera |
13-Sep-2010 |
| Incyte to Present at Upcoming Investor Conferences |
2-Sep-2010 |
| Incyte Reports Second Quarter 2010 Financial Results |
5-Aug-2010 |
| Incyte to Report Second Quarter 2010 Financial Results and Provide
Update on Drug Discovery & Development Programs on August 5 |
20-Jul-2010 |
| Results from an Ongoing Phase I/II Trial of Oral INCB7839 Presented
at ASCO |
6-Jun-2010 |
| Incyte to Present at Upcoming Investor Conferences |
27-May-2010 |
| Incyte Appoints Wendy Dixon, Ph.D., to Its Board of Directors |
25-May-2010 |
| Incyte to Present at the Citi Investment Research 2010 Global Health
Care Conference |
18-May-2010 |
| Incyte Reports First Quarter 2010 Financial Results |
6-May-2010 |
| Incyte to Present at the 2010 Bank of America Merrill Lynch Health
Care Conference |
3-May-2010 |
| Incyte to Report First Quarter 2010 Financial Results and Provide
Update on Drug Discovery & Development Programs on May 6 |
22-Apr-2010 |
| Incyte to Present at the Cowen and Company 30th
Annual Health Care Conference |
25-Feb-2010 |
| Incyte Reports 2009 Financial Results; Strengthens Balance Sheet;
Provides 2010 Financial Guidance |
18-Feb-2010 |
| Incyte to Report 2009 Financial Results and 2010 Financial Guidance
and Provide Update on Drug Discovery & Development Programs
on February 18 |
9-Feb-2010 |
| Incyte Announces Redemption of Its 3½% Convertible Senior Notes Due
2011 and Its 3½% Convertible Subordinated Notes Due 2011 |
28-Jan-2010 |
| Incyte to Present at the 28th Annual
JPMorgan Healthcare Conference |
5-Jan-2010 |
| Incyte to Host Conference Call to Discuss Its Collaboration with Lilly for the Development and Commercialization of Oral Anti-Inflammatory and Autoimmune Therapies |
21-Dec-2009 |
| Lilly and Incyte Announce Collaboration for Development and Commercialization of Oral Anti-Inflammatory and Autoimmune Therapies |
21-Dec-2009 |
| Data from a Phase I/II Study Presented at the 32nd
San Antonio Breast Cancer Symposium Suggest that INCB7839 in Combination
with Trastuzumab May Improve Clinical Response Rates in HER2 Positive
Patients with Advanced Metastatic Disease |
12-Dec-2009 |
| Data from Three Phase II Trials to be Presented at the 51st American Society of Hematology Annual Meeting Demonstrate that INCB18424, a Selective JAK1/JAK2 Inhibitor, Has Potential in Multiple Hematology Conditions |
7-Dec-2009 |
| Incyte to Host Webcast at 51st American Hematology Annual Meeting |
2-Dec-2009 |
| Incyte Announces Major Collaboration and License Agreement for Two Hematology-Oncology Programs |
25-Nov-2009 |
| Incyte Reports Third Quarter 2009 Financial Results and Provides Update on Drug Development Programs |
5-Nov-2009 |
| Incyte to Report Third Quarter 2009 Financial Results and Provide Update on Drug Discovery & Development Programs on November 5 |
20-Oct-2009 |
| Incyte to Present at the Fourth Annual JMP Securities Healthcare Focus Conference |
30-Sep-2009 |
| Incyte Announces Closing of Public Offering of Common Stock |
30-Sep-2009 |
| Incyte Completes Offering of Convertible Senior Notes |
30-Sep-2009 |
| Incyte Prices $350 Million Convertible Senior Notes Offering |
24-Sep-2009 |
| Incyte Announces Pricing of Public Offering of 18,000,000 Shares of Common Stock |
24-Sep-2009 |
| Incyte Announces Proposed Public Offering of 18,000,000 Shares of Common Stock |
22-Sep-2009 |
| Incyte Announces Proposed Offering of $250 Million Convertible Senior Notes |
22-Sep-2009 |
| Incyte Announces Positive Top-Line Phase IIb Results for Topical INCB18424 in Psoriasis |
21-Sep-2009 |
| Incyte to Present at Upcoming Investor Conferences |
3-Sep-2009 |
| Incyte Reports Second Quarter 2009 Financial Results and Provides Update on Drug Development Programs |
30-Jul-2009 |
| Incyte Reaches Agreement with FDA on a Special Protocol Assessment for INCB18424 in Myelofibrosis |
21-Jul-2009 |
| Incyte to Report Second Quarter 2009 Financial Results and Provide Update on Drug Discovery & Development Programs on July 30 |
15-Jul-2009 |
| Results Presented at the ADA 69th Scientific Sessions Demonstrate that INCB13739, Incyte's Oral 11beta-HSD1 Inhibitor, Significantly Improves Glycemic Control, Insulin Sensitivity and Total Cholesterol in Patients with Type 2 Diabetes |
6-Jun-2009 |
| Incyte Provides Update on Special Protocol Assessment for INCB18424 as a New Treatment for Myelofibrosis |
28-May-2009 |
| Incyte to Present at Goldman Sachs 30th Annual Global Healthcare Conference |
26-May-2009 |
| Incyte Reports First Quarter 2009 Financial Results and Provides Update on Drug Development Programs |
7-May-2009 |
| Incyte to Report First Quarter 2009 Financial Results and Provide Update on Drug Discovery & Development Programs on May 7 |
21-Apr-2009 |
| Incyte to Present at Citi's 4th Annual Biotech Day Conference |
24-Mar-2009 |
| Incyte to Present at Cowen and Company 29th Annual Health Care Conference |
9-Mar-2009 |
| Incyte Reports Fourth Quarter and Year-End 2008 Financial Results; Announces 2009 Financial Guidance |
18-Feb-2009 |
| Incyte to Report 2008 Financial Results and 2009 Financial Guidance and Provide Update on Drug Discovery & Development Programs on February 18 |
4-Feb-2009 |
| Incyte to Announce 2009 Objectives at JPMorgan Healthcare Conference; JAK Inhibitor Program Highest Priority |
13-Jan-2009 |
| Incyte to Present at the 27th Annual JPMorgan Healthcare Conference |
5-Jan-2009 |
| Incyte's Selective JAK1 / 2 Inhibitor, INCB18424, Demonstrates Rapid and Durable Clinical Benefits in Myelofibrosis Patients |
6-Dec-2008 |
| Incyte to Present at the 20th Annual Piper Jaffray Health Care Conference |
20-Nov-2008 |
| Incyte Reports Progress in Multiple Clinical Programs Announces Third Quarter Financial Results |
6-Nov-2008 |
| Incyte to Present at 2008 DB-Biotech Boston Confab |
30-Oct-2008 |
| Incyte's JAK Inhibitor Demonstrates Rapid and Marked Clinical Improvement in Rheumatoid Arthritis Patients |
26-Oct-2008 |
| Incyte to Report Third Quarter 2008 Financial Results and Provide Update on Drug Discovery & Development Programs on November 6 |
23-Oct-2008 |
| Incyte to Host Webcast and Conference Call on October 26, 10:30 p.m. Eastern Time / 7:30 p.m. Pacific Time |
23-Oct-2008 |
| Incyte to Present at JMP Securities Third Annual Healthcare Focus Conference |
30-Sep-2008 |
| Incyte Appoints Chief Commercial Officer |
18-Sep-2008 |
| Incyte's Topical JAK Inhibitor Demonstrates Positive Proof-of-Concept Results in Patients with Mild to Moderate Psoriasis |
18-Sep-2008 |
| Incyte to Present at the UBS Global Life Sciences Conference |
16-Sep-2008 |
| Incyte to Present at Upcoming Investor Conferences |
27-Aug-2008 |
| Incyte Announces Closing of Public Offering of Common Stock |
6-Aug-2008 |
| Incyte Announces Pricing of Public Offering of 10,500,000 Shares of Common Stock |
31-Jul-2008 |
| Incyte Announces Proposed Public Offering of 9,000,000 Shares of Common Stock |
29-Jul-2008 |
| Incyte Reports Progress in Multiple Clinical Programs; Announces Second Quarter Financial Results |
29-Jul-2008 |
| Incyte to Report Second Quarter 2008 Financial Results and Provide Update on Drug Discovery & Development Programs on July 31 |
22-Jul-2008 |
| Incyte's JAK Inhibitor Demonstrates Marked Clinical Benefits in Phase IIa Rheumatoid Arthritis Study |
12-Jun-2008 |
| Incyte to Host EULAR Webcast and Conference Call on June 12 |
11-Jun-2008 |
| Incyte's Selective Oral Inhibitor of 11beta-HSD1 Demonstrates Improvements in Insulin Sensitivity and Lowers Cholesterol Levels in Type 2 Diabetics |
9-Jun-2008 |
| Incyte to Present at Upcoming Investor Conferences |
3-Jun-2008 |
| Incyte's Novel JAK Inhibitor Demonstrates Rapid Clinical Benefits in Ongoing Phase I/II Myelofibrosis Study |
2-Jun-2008 |
| Incyte Reports First Quarter Financial Results and Positive Clinical Progress in Multiple Programs |
30-Apr-2008 |
| Incyte to Report First Quarter 2008 Financial Results and Provide Update on Drug Discovery & Development Programs on April 30 |
17-Apr-2008 |
| Incyte to Present at Upcoming Investor Conferences |
17-Apr-2008 |
| Incyte to Provide Update on Clinical Programs at Cowen Health Care Conference |
17-Mar-2008 |
| Incyte to Present at the Cowen and Company 28th Annual Health Care Conference |
11-Mar-2008 |
| Incyte Reports Progress in Multiple Clinical Programs; Expands JAK Inhibitor Program; Announces 2007 Financial Results and Provides 2008 Financial Guidance |
14-Feb-2008 |
| Incyte to Report 2007 Financial Results and 2008 Financial Guidance and Provide Update on Drug Discovery & Development Programs on February 14 |
5-Feb-2008 |
| Incyte to Report Positive Clinical Results from JAK Inhibitor and 11beta-HSD1 Inhibitor Programs and Introduce New Metabolic Program at JPMorgan Healthcare Conference |
8-Jan-2008 |
| Incyte to Present at the 26th Annual JPMorgan Healthcare Conference |
2-Jan-2008 |
| Incyte Announces $8.5 million Gain from Sale of Investment |
21-Dec-2007 |
| Data Presented at the 30th San Antonio Breast Cancer Symposium Supports Further Development of INCB7839 as a New Oral Treatment for Breast Cancer |
16-Dec-2007 |
| Data Presented At The American Society Of Hematology 49th Meeting Demonstrate That Incyte's Novel JAK Inhibitor, INCB18424, Provides Rapid and Profound Clinical Benefits in Myelofibrosis Patients |
10-Dec-2007 |
| Incyte To Webcast A Discussion Of Its JAK Inhibitor, INCB18424, During The American Society Of Hematology 49th Annual Meeting |
5-Dec-2007 |
| Incyte to Present at the Piper Jaffray 19th Annual Health Care Conference |
20-Nov-2007 |
| Incyte Reviews Positive Proof-of-Concept Clinical Results Achieved During the Third Quarter; Cites Continued Progress in Multiple Drug Development Programs; Announces Third Quarter Financial Results |
1-Nov-2007 |
| Incyte to Report Third Quarter 2007 Financial Results and Provide Update on Drug Discovery & Development Programs on November 1 |
11-Oct-2007 |
| Incyte Receives $10 million from the Sale of a Convertible Subordinated Note to Pfizer with the Filing and Acceptance of an IND for INCB8696, Its Lead CCR2 Antagonist |
10-Oct-2007 |
| Incyte Reports Positive Proof-of-Concept Results For INCB18424, Its Lead JAK Inhibitor, and INCB13739, its Lead 11beta-HSD1 Inhibitor |
25-Sep-2007 |
| Data Presented at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Demonstrate That INCB9471 is a Potent, Selective Inhibitor of the HIV-1 Virus with Excellent Pharmacokinetics Suitable for Once-Daily Dosing |
18-Sep-2007 |
| Incyte to Present at the 2007 UBS Global Life Sciences Conference |
17-Sep-2007 |
| Incyte Cites Encouraging Clinical Data in Multiple Programs; Announces Second Quarter 2007 Financial Results |
26-Jul-2007 |
| Phase IIa Study Results Demonstrate that Once-Daily 200 mg Dosing of INCB9471 Provided Potent and Prolonged Antiviral Activity in HIV-Infected Patients |
24-Jul-2007 |
| Incyte to Report Second Quarter 2007 Financial Results and Provide Update on Drug Discovery & Development Programs on July 26 |
9-Jul-2007 |
| Incyte to Present at Upcoming Investor Conferences |
4-Jun-2007 |
| Incyte to Present at Upcoming Investment Conferences |
17-May-2007 |
| Incyte Reviews Progress in Multiple Drug Development Programs and Announces First Quarter 2007 Financial Results |
3-May-2007 |
| Incyte to Present at the Morgan Stanley Global Healthcare Unplugged Conference |
23-Apr-2007 |
| Incyte to Report First Quarter 2007 Financial Results and Provide Update on Drug Discovery & Development Programs on May 3 |
18-Apr-2007 |
| Incyte Reviews Recent Progress in Multiple Programs; Announces 2006 Financial Results and 2007 Financial Guidance |
15-Feb-2007 |
| Incyte to Report 2006 Financial Results and 2007 Financial Guidance and Provide Update on Drug Discovery & Development Programs on February 15 |
24-Jan-2007 |
| Incyte to Report Positive Preliminary Clinical Results from HIV and Diabetes Programs and Highlight Progress in Several Drug Development Programs at the 25th JPMorgan Healthcare Conference |
8-Jan-2007 |
| Incyte to Present at the 25th Annual JP Morgan Healthcare Conference |
4-Jan-2007 |
| Registration Statement Declared Effective for the Resale of Incyte's 3 1/2% Convertible Senior Notes Originally Issued in September 2006 |
8-Dec-2006 |
| Incyte to Present at 18th Annual Piper Jaffray Health Care Conference |
27-Nov-2006 |
| Incyte Announces Filing of Registration Statement for Resale of 3 1/2% Convertible Senior Notes due 2011 |
21-Nov-2006 |
| Incyte to Present at JMP Securities Healthcare Conference |
13-Nov-2006 |
| Incyte Reports Continued Progress in Multiple Drug Discovery and Development Programs; Announces Third Quarter Financial Results |
2-Nov-2006 |
| Incyte to Report Third Quarter 2006 Financial Results and Provide Update on Drug Discovery & Development Programs on November 2 |
20-Oct-2006 |
| Incyte Completes Note Offering and Announces Redemption of Outstanding 5.5% Convertible Subordinated Notes Due 2007 |
26-Sep-2006 |
| Incyte to Present at UBS Global Life Sciences Conference |
21-Sep-2006 |
| Incyte Announces Offering of Convertible Senior Notes; Net Proceeds to Be Used to Redeem Its Outstanding 5.5% Convertible Subordinated Notes Due February 1, 2007 |
20-Sep-2006 |
| Incyte to Present at Thomas Weisel Partners Healthcare Conference |
29-Aug-2006 |
| Incyte Announces Second Quarter Financial Results; Provides Update on Drug Discovery and Development Programs; Conference Call and Webcast Scheduled for 8:30 a.m. ET Today |
27-Jul-2006 |
| Incyte to Report Second Quarter 2006 Financial Results; Provide Update on Drug Discovery & Development Programs on July 27 |
10-Jul-2006 |
| Incyte Invites Investors to Listen to Webcast of Presentation at the Jefferies Life Sciences Conference |
22-Jun-2006 |
| Incyte Begins Phase I Study of INCB13739 as a New Treatment for Type 2 Diabetes |
7-Jun-2006 |
| Incyte to Present at Needham Conference |
6-Jun-2006 |
| Incyte Stockholders Elect Two New Directors |
23-May-2006 |
| Incyte Begins Phase I Study of New HIV Drug in Healthy Volunteers |
10-May-2006 |
| Incyte Invites Investors to Listen to Webcast of Presentation at the Bank of America 2006 Health Care Conference |
8-May-2006 |
| Incyte Announces First Quarter Financial Results and Provides Update on Drug Discovery and Development Programs; Conference Call and Webcast Scheduled for 8:30 a.m. ET Today |
4-May-2006 |
| Incyte Invites Investors to Listen to Webcast of Presentation at the Morgan Stanley Global Healthcare Unplugged Conference |
24-Apr-2006 |
| Incyte to Report First Quarter 2006 Financial Results; Provide Update on Drug Discovery & Development Programs on May 4 |
21-Apr-2006 |
| Incyte to Discontinue Development of DFC as a Treatment for HIV; Conference Call Scheduled for 8:30 a.m. ET Today |
3-Apr-2006 |
| Incyte to Present at Upcoming Investor Conferences |
21-Feb-2006 |
| Incyte Announces 2005 Financial Results and Provides 2006 Guidance; Initiates Study 204 for DFC in Treatment-Experienced HIV Patients and Receives $50 Million from CCR2 Alliance with Pfizer |
16-Feb-2006 |
| Incyte to Report 2005 Financial Results and 2006 Financial Guidance; Provide Update on Drug Discovery & Development Programs on February 16 |
25-Jan-2006 |
| Incyte to Present at the 24th Annual JPMorgan Healthcare Conference |
5-Jan-2006 |
| Incyte to Host Conference Call Today to Discuss Collaborative Research and License Agreement with Pfizer for the Development and Commercialization of CCR2 Antagonists; Conference Call is Scheduled to Begin at 8:30 a.m. ET Today |
21-Nov-2005 |
| Pfizer and Incyte Enter Collaborative Research and License Agreement for the Development and Commercialization of CCR2 Antagonists |
21-Nov-2005 |
| Incyte Announces Third Quarter 2005 Results; Provides Update on Most Advanced Drug Development Programs and Reduces Cash Use Guidance for 2005; Conference Call and Webcast Scheduled for 8:30 a.m. ET Today |
1-Nov-2005 |
| Incyte to Report Third Quarter 2005 Financial Results on November 1 |
19-Oct-2005 |
| Incyte Announces Outcome of Discussions with FDA Regarding Reverset(TM) |
28-Sep-2005 |
| Incyte to Present at Investor Conferences in September |
31-Aug-2005 |
| Incyte Announces Second Quarter 2005 Financial Results; Reports Positive Phase IIb Results for Reverset in Treatment-Experienced HIV Patients |
1-Aug-2005 |
| Incyte to Report Second Quarter 2005 Financial Results on August 1, Update Investors at Meeting in New York on August 2 |
25-Jul-2005 |
| Phase IIb Study Shows Reverset(TM) Has Potent Antiviral Activity in Treatment-Experienced HIV Patients Failing Current Treatment Regimen; Findings Presented at the 3rd International AIDS Society Conference |
25-Jul-2005 |
| Results from Reverset Study 203 Accepted for Late Breaker Presentations at 3rd International AIDS Society Conference in Rio de Janeiro |
7-Jul-2005 |
| Incyte Invites Investors to Listen to Webcast of Presentation at Goldman Sachs Conference |
31-May-2005 |
| Incyte Announces First Quarter 2005 Results; Progress Achieved in Top Three Drug Development Programs; Conference Call and Webcast Scheduled for 8:30 a.m. ET Today |
4-May-2005 |
| Incyte to Present at Upcoming Investor Conferences |
27-Apr-2005 |
Incyte to Report First Quarter 2005 Financial Results
on May 4 |
11-Apr-2005 |
| Incyte Begins Phase I Study in Healthy Volunteers of Novel Oral Cancer Compound, INCB7839 |
6-Apr-2005 |
Incyte to Present at Lehman and BioCentury
Conferences |
24-Mar-2005 |
| Incyte Provides Update on Most Advanced Discovery and Development Programs; Announces 2004 Financial Results and Provides 2005 Guidance |
28-Feb-2005 |
| Incyte to Present at Several Upcoming Investor Conferences |
22-Feb-2005 |
| Incyte to Report 2004 Financial Results and 2005 Financial Guidance; Provide Update on Discovery & Development Programs on February 28 |
9-Feb-2005 |
| Incyte to Present at the Piper Jaffray Health Care Conference |
20-Jan-2005 |
| BIOBASE Acquires the Proteome Subsidiary of Incyte |
18-Jan-2005 |
| Incyte to Present at the 23rd Annual JPMorgan Healthcare Conference |
7-Jan-2005 |
| Incyte to Participate in the Punk, Ziegel & Company Investor Symposium on New Agents to Treat HIV |
19-Nov-2004 |
| Incyte Announces Third Quarter Financial Results; Conference Call and Webcast Scheduled for 8:30 a.m. ET Today |
4-Nov-2004 |
| Incyte Announces Pricing of Common Stock Offering |
1-Nov-2004 |
| Incyte Commences Public Offering of Common Stock |
1-Nov-2004 |
| Results of Phase IIa Study Show That Reverset Has Potential to Reduce HIV Viral Load in Treatment-Experienced Patients |
31-Oct-2004 |
| Incyte to Present at the CIBC World Markets Fifteenth Annual Heathcare Conference |
28-Oct-2004 |
| Incyte to Report Third Quarter 2004 Financial Results on November 4 |
28-Oct-2004 |
| Incyte Announces Filing of $175 Million Shelf Registration |
7-Oct-2004 |
| Incyte to Present at the 2004 UBS Global Life Sciences Conference |
21-Sep-2004 |
| Incyte to Present at the Thomas Weisel Partners Healthcare Tailwinds 2004 Conference |
26-Aug-2004 |
| Incyte Announces Second Quarter Financial Results; Provides Update on Reverset and INCB3284, Incyte's Phase I CCR2 Antagonist |
4-Aug-2004 |
| Incyte to Report Second Quarter 2004 Financial Results |
26-Jul-2004 |
| Incyte Announces Effectiveness of Registration Statement for Resale of 3- 1/2% Convertible Subordinated Notes due 2011 |
15-Jul-2004 |
| Results of Phase II Study Presented at the XV International AIDS Conference Demonstrate Reverset Has Potential to Reduce Viral Load in Treatment-Naive and Treatment-Experienced HIV Patients |
12-Jul-2004 |
| Incyte to Present at the Third Annual Needham Biotechnology Conference |
14-Jun-2004 |
| Incyte to Present at the SunTrust Robinson Humphrey 33rd Annual Institutional Conference |
25-May-2004 |
| Incyte to Present at the Banc of America Health Care Conference |
18-May-2004 |
| Incyte Initiates Phase I Testing of Oral CCR2 Antagonist; Growing Body of Evidence Suggests CCR2 Antagonists May Have Therapeutic Value in a Number of Chronic Inflammatory Diseases |
11-May-2004 |
| Incyte to Present at the SunTrust Robertson Humphrey Therapeutics Conference |
7-May-2004 |
| Incyte Announces First Quarter 2004 Financial Results, Provides Update on Most Advanced Drug Discovery and Development Programs |
4-May-2004 |
| Incyte to Present at the Morgan Stanley HealthCare Unplugged Conference |
29-Apr-2004 |
| Incyte to Report First Quarter 2004 Financial Results |
26-Apr-2004 |
| Incyte Announces Filing of Registration Statement for Resale of 3- 1/2% Convertible Subordinated Notes Due 2011 |
26-Apr-2004 |
| Incyte Completes Sale of an Additional $50 Million of Convertible Subordinated Notes |
8-Mar-2004 |
| Incyte To Present At Lehman Brothers Seventh Annual Global Healthcare Conference |
1-Mar-2004 |
| Incyte Prices $200 Million Convertible Subordinated Notes Offering |
12-Feb-2004 |
| Reverset Data Presented at the 11th Annual Conference on Retroviruses and Opportunistic Infections Demonstrate Potent Antiviral Effects in Treatment-Naive HIV Patients |
11-Feb-2004 |
| Incyte Announces Proposed Offering of $150 Million Convertible Subordinated Notes |
11-Feb-2004 |
| Incyte to Host Conference Call to Discuss Clinical Results From a Phase II Study of Reverset in HIV-Infected Patients |
11-Feb-2004 |
| Incyte and Pharmasset Announce Preliminary Findings from Phase II Study of Reverset in HIV-Infected Patients; Once-Daily Dosing Results in Significant Reduction in Viral Load |
7-Feb-2004 |
| Incyte to Close Palo Alto Facilities, Reduce Workforce by 57 Percent, Focus Resources on Drug Discovery and Development |
2-Feb-2004 |
| Incyte to Report 2003 Financial Results and Provide 2004 Financial Guidance on February 2nd |
30-Jan-2004 |
| Incyte and Roche Diagnostics Sign Agreement; Roche Diagnostics will License Incyte's Linear RNA Amplification Technologies for Gene Expression Profiling |
15-Jan-2004 |
| Incyte Announces New General Counsel |
16-Dec-2003 |
| Company Profile for Incyte Corporation |
7-Nov-2003 |
| Incyte Reports Third Quarter 2003 Financial Results; Expands Pipeline, Advances CCR2 Receptor Antagonist Program |
4-Nov-2003 |
| Incyte to Report Third Quarter 2003 Financial Results on November 4th |
10-Oct-2003 |
| Incyte To Provide Disease-Specific Data Free of Charge |
10-Oct-2003 |
| Incyte Appoints David C. Hastings As Chief Financial Officer |
1-Oct-2003 |
| Incyte To Present At The UBS Global Life Sciences Conference |
22-Sep-2003 |
| Incyte Announces New Senior Management Post |
10-Sep-2003 |
| Incyte and Pharmasset Enter into a Collaborative Licensing Agreement for a Phase II HIV Drug |
8-Sep-2003 |
| Incyte To Present At The BioCentury NewsMakers Conference |
28-Aug-2003 |
| Incyte Appoints Richard Levy, M.D. Senior Vice President, Drug Development |
26-Aug-2003 |
| Incyte Announces Management Change |
22-Aug-2003 |
| Incyte Launches Information Product Enhancements for LifeSeq® Foundation and Proteome BioKnowledge® Library |
11-Aug-2003 |
| Incyte Reports Second Quarter 2003 Financial Results; Progress in Drug Discovery, Information Product Development |
30-Jul-2003 |
| Incyte to Report Second Quarter 2003 Financial Results on July 30th |
21-Jul-2003 |
| Richard U. De Schutter Elected Chairman of Incyte Corporation Board of Directors |
24-Jun-2003 |
| Incyte Presentation At the Needham & Company Second Annual Biotechnology Conference to Be Webcast Live |
2-Jun-2003 |
| Incyte Reports First Quarter 2003 Financial Results |
5-May-2003 |
| Incyte Presentation At Deutsche Bank Health Care Conference To Be Webcast Live |
24-Apr-2003 |
| Incyte Launches New Corporate Web Site |
24-Apr-2003 |
| Incyte To Report First Quarter 2003 Financial Results On May 5, 2003 |
21-Apr-2003 |
| Incyte To Present At Lehman Brothers Sixth Annual Global Healthcare Conference |
3-Mar-2003 |
| Incyte to Present at the BIO CEO & Investor Conference |
24-Feb-2003 |
| Incyte Reports 2002 Financial Results, Provides Outlook for 2003 |
19-Feb-2003 |
| Incyte Acquires Maxia Pharmaceuticals; Acquisition Expands Drug Discovery & Development Programs |
19-Feb-2003 |
| Incyte Expands Proteome BioKnowledge Library with Information Linking Human Protein Function to Disease; New Offering Helps Research Scientists Prioritize Drug Targets |
4-Feb-2003 |
| Incyte Genomics to Report Fourth Quarter 2002 Financial Results on February 19, 2003 |
30-Jan-2003 |
| Incyte to Webcast Presentation From the 21st Annual JP Morgan H&Q Healthcare Conference |
6-Jan-2003 |
| Incyte Genomics to Become Incyte Corporation; Shift from `Genomics' Reflects Drug Discovery Progress and New Information Products |
16-Dec-2002 |
| Incyte Announces $88 Million Expense Reduction, Launch of Its First Drug Discovery Program and Third Quarter 2002 Financial Results |
12-Nov-2002 |
| Incyte Announces Agreement to Acquire Maxia Pharmaceuticals |
12-Nov-2002 |
| Incyte Genomics to Report Third Quarter 2002 Financial Results On November 12 |
31-Oct-2002 |
| Incyte Genomics Issues Revised Financial Guidance for Fiscal 2002 |
4-Sep-2002 |
| Incyte Genomics Reports Financial Results for the Second Quarter of Fiscal 2002 |
25-Jul-2002 |
| Incyte Genomics and the University of Cambridge Report New Cause of Severe Insulin Resistance; Findings Have Implications for the Treatment of Type 2 Diabetes |
15-Jul-2002 |
| Incyte Genomics Sets Date for Second Quarter Fiscal 2002 Earnings Announcement |
11-Jul-2002 |
| Incyte Genomics Reports Financial Results for the First Quarter of Fiscal 2002 |
1-May-2002 |
| GeneFormatics and Incyte Genomics Sign Collaborative Agreement to Annotate Functions of Protein Sequences |
23-Apr-2002 |
| Incyte Sets Date for First Quarter Fiscal 2002 Earnings Announcement |
18-Apr-2002 |
| Incyte Genomics and LION bioscience Collaborate to Provide Broader Access to Drug Target Information |
2-Apr-2002 |
| Leading Genomic Research Firm Chooses Delaware As Location For New East Coast Facility |
4-Mar-2002 |
| First Comprehensive Chemogenomics System for Drug Discovery and Optimization Launched; DrugMatrix Introduced by Incyte Genomics and Iconix Pharmaceuticals |
25-Feb-2002 |
| Ambion Licenses RNA Amplification Patents from Incyte Genomics |
14-Feb-2002 |
| Incyte Reports 2001 Fourth Quarter and Year End Financial Results |
13-Feb-2002 |
| Brian Metcalf, Ph.D., Appointed Executive Vice President and Chief Drug Discovery Scientist for Incyte Genomics; Dr. Metcalf Also Named Site Head for Incyte's New East Coast Operations |
7-Feb-2002 |
| Incyte Sets Announcement Date for Fourth Quarter Fiscal 2001 Earnings Release |
4-Feb-2002 |
| Incyte Genomics Appoints Richard U. De Schutter and Paul A. Brooke to its Board of Directors |
14-Jan-2002 |
| Incyte Genomics Presentation to be Webcast by JP Morgan H&Q from its 20th Annual Healthcare Conference |
4-Jan-2002 |
| Affymetrix and Incyte Genomics Settle All Patent Infringement Litigation |
21-Dec-2001 |
| Cambridge Antibody Technology Gains Access To Incyte LifeSeq® Gold Database And Options To Develop And Commercialize Human Therapeutic Antibody Products |
19-Dec-2001 |
| Incyte Genomics Names Paul A. Friedman, M.D., Chief Executive Officer and Robert Stein, M.D., Ph.D., President and Chief Scientific Officer |
26-Nov-2001 |
| Dr. Reddy's Laboratories Limited Announce Agreement for Utilizing Incyte LifeSeq® Gold Online |
20-Nov-2001 |
| Incyte Genomics Reports Record Revenues for Third Quarter 2001 |
25-Oct-2001 |
| Incyte Genomics Reschedules Third Quarter Fiscal 2001 Results Release and Conference Call |
23-Oct-2001 |
| Incyte Genomics Signs Exclusive Patent Agreement with Genentech to Enable Commercialization of Therapeutic Antibodies to Four Proteins |
23-Oct-2001 |
| Medarex and Incyte Genomics Announce Partnership to Develop and Commercialize Fully Human Antibody Therapeutics |
18-Oct-2001 |
| Incyte Genomics Receives Favorable Court Ruling Invalidating Affymetrix Patent |
15-Oct-2001 |
| Incyte Genomics and Epoch Biosciences Enter into License, Development and Supply Alliance |
10-Oct-2001 |
 |
